Condition: Myopia · Sponsor: Eyenovia Inc.
This study evaluates the progression of myopia in participants using microdosed atropine 0.01%, atropine 0.1%, or placebo ophthalmic solution. Eligible subjects will administer study medication daily in each eye for 48 months. Efficacy and safety assessments will be performed at visits scheduled for 1, 6, 12, 18, 24, 30 and 36 months after initiation of medication use. Subjects will be re-randomized at the 36 month visit, then followed at 6 month intervals for an additional year.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham School of Optometry | Birmingham, Alabama, United States | — |
| Midwestern University | Glendale, Arizona, United States | — |
| Canyon City Eyecare | Azusa, California, United States | — |
| UC Berkeley | Berkeley, California, United States | — |
| Marshall Ketchum University College of Optometry | Los Angeles, California, United States | — |
| Ratner Children's Eye Center | San Diego, California, United States | — |
| Illinois College of Optometry | Chicago, Illinois, United States | — |
| Midwestern University | Downers Grove, Illinois, United States | — |
| SUNY College of Optometry | New York, New York, United States | — |
| Wake Forest Health Network Ophthalmology - Oak Hollow | High Point, North Carolina, United States | — |
| Oculus Research | Raleigh, North Carolina, United States | — |
| The Ohio State University - College of Optometry | Columbus, Ohio, United States | — |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03942419